SCHEMBL1108549

SCHEMBL1108549

COc1ccc(Oc2ccc(S(=O)(=O)N(C)C[C@@H]3NC(=O)NC3=O)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.44
LMNA P02545 6/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
HTT P42858 3/20 0.42
ALDH1A1 P00352 3/20 0.42
MMP2 P08253 2/20 0.41
MMP9 P14780 2/20 0.41
MMP3 P08254 1/20 0.41
MMP13 P45452 1/20 0.41
NR3C1 P04150 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
PSEN1 P49768 2/20 0.39
PSEN2 P49810 2/20 0.39
APH1B Q8WW43 2/20 0.39
NCSTN Q92542 2/20 0.39
APH1A Q96BI3 2/20 0.39
PSENEN Q9NZ42 2/20 0.39
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1100371 1.00 PGR (0.44) PGRLMNASMN1; SMN2HTTALDH1A1
SCHEMBL1098732 0.91 PGR (0.46) PGRLMNASMN1; SMN2HTTALDH1A1
SCHEMBL1108464 0.91 LMNA (0.42) LMNASMN1; SMN2HTTALDH1A1MMP2
SCHEMBL1099181 0.91 LMNA (0.42) LMNASMN1; SMN2HTTALDH1A1MMP2
SCHEMBL1108503 0.91 PGR (0.46) PGRLMNASMN1; SMN2HTTALDH1A1
SCHEMBL1108535 0.89 FFAR1 (0.45) LMNASMN1; SMN2HTTALDH1A1MMP2
SCHEMBL1100932 0.89 FFAR1 (0.45) LMNASMN1; SMN2HTTALDH1A1MMP2
SCHEMBL1101042 0.88 LMNA (0.40) PGRLMNASMN1; SMN2HTTALDH1A1
SCHEMBL1108565 0.88 LMNA (0.40) PGRLMNASMN1; SMN2HTTALDH1A1
SCHEMBL1099733 0.86 CACNA1H (0.43) PGRLMNASMN1; SMN2HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 US disclosed
US-8153673-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2012-04-10 US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 US disclosed
US-20100273849-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2010-10-28 US disclosed
US-7666892-B2 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2010-02-23 US disclosed
US-20080262045-A1 Metalloproteinase Inhibitors ASTRAZENECA AB (SE) 2008-10-23 US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 US disclosed
US-7368465-B2 Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders ASTRAZENECA AB (SE) 2008-05-06 US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 US disclosed
US-20040138276-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273849-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 PGR 3527/4885LMNA 2791/4885SMN1; SMN2 1262/4885
US-20080262045-A1 Metalloproteinase Inhibitors MMP9, MMP12, MMP11 PGR 3527/4885LMNA 2791/4885SMN1; SMN2 1262/4885
US-20040138276-A1 Metalloproteinase inhibitors MMP9, MMP11, MMP7 PGR 2805/4885LMNA 2081/4885SMN1; SMN2 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.